SEOUL (Reuters) – South Korea’s Samsung Biologics announced on Tuesday two deals with Pfizer worth around a combined 1.2 trillion won ($921.38 million) to manufacture products for the U.S. pharmaceutical…
(Reuters) – The Biden administration said Thursday it had removed Wuxi Biologics, a company that makes ingredients for AstraZeneca’s COVID-19 vaccine, and about two dozen other Chinese entities from a…
(Reuters) – Innovent Biologics Inc said on Friday Paris-based Sanofi SA would invest HK$2.42 billion ($307.88 million) in the biopharmaceutical group to jointly develop two cancer drugs in China. The…
BEIJING – WuXi Biologics said in a statement on Tuesday on WeChat that two of its subsidiaries being put on the U.S. Commerce Department’s “unverified list” will have no impact…